Monitoring Circulating Tumor Cells With The CellSearch System Can Predict Prognosis In Metastatic Breast Cancer

RARITAN, N.J. -- Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncology. The retrospective study compared how well CTCs and a more sensitive than conventional modality, fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), predicted survival in MBC patients on standard therapies. The comparison showed that both technologies significantly correlate to overall MBC patient survival (pThe CellSearch(R) System is the first 510(k) diagnostic test used to automate the capture and detection of CTCs, tumor ce...